ArticleEBioMedicine2018
Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic accuracy of circulating long noncoding RNAs in hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Combinatorial Gene Expression Profiling of SerumInternational journal of molecular sciences · 2024Pooled it
- Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. A systematic review.Medicina oral, patologia oral y cirugia bucal · 2020Pooled it
- LncRNA FOXP4-AS1 facilitates colorectal cancer invasion and migration by enhancing USP7 interaction with ZEB1.Scientific reports · 2026Article
- The regulation of hypoxia-related lncRNAs in hepatocellular carcinoma.Discover oncology · 2024Review
- Review
- "Salivary LINC00657 and miRNA-106a as diagnostic biomarkers for oral squamous cell carcinoma, an observational diagnostic study".BMC oral health · 2023Article
- [Research and exploration of salivary biological markers for hepatitis B-related hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Combining a machine-learning derived 4-lncRNA signature with AFP and TNM stages in predicting early recurrence of hepatocellular carcinoma.BMC genomics · 2023Article
- Promising applications of human-derived saliva biomarker testing in clinical diagnostics.International journal of oral science · 2023Review
- Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma.Scientific reports · 2022Article
- Circ_0084043-miR-134-5p axis regulates PCDH9 to suppress melanoma.Frontiers in oncology · 2022Article
- The roles of lncRNA functions and regulatory mechanisms in the diagnosis and treatment of hepatocellular carcinoma.Frontiers in cell and developmental biology · 2022Review
- HCC biomarkers - state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice.Frontiers in oncology · 2022Review
- PCDH9 suppresses melanoma proliferation and cell migration.Frontiers in oncology · 2022Article
- Decoding the Roles of Long Noncoding RNAs in Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- The Clinical Potential of Oral Microbiota as a Screening Tool for Oral Squamous Cell Carcinomas.Frontiers in cellular and infection microbiology · 2021Article
- The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- A Novel Post-Operative ALRI Model Accurately Predicts Clinical Outcomes of Resected Hepatocellular Carcinoma Patients.Frontiers in oncology · 2021Article
- Clinical Significance and Potential Role ofFrontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong non-coding RNAs (lncRNAs) show great potential as diagnostic tools in many diseases. We aimed to develop sensitive and noninvasive biomarkers in saliva for detecting early hepatocellular carcinoma (HCC).
methodsCandidate lncRNA biomarkers identified by Agilent microarray were subjected to validation using qPCR for the quantification of their expression levels in independent tissue, plasma and saliva sample sets, including healthy controls, HBsAg carriers, patients with chronic Hepatitis B, liver cirrhosis, early HCC, and advanced HCC. Levels of candidate biomarkers were also measured in totally 108 saliva samples from patients with any one of other nine leading causes of cancer death in men and women.
findingsLnc-PCDH9-13:1 was significantly elevated in HCC tissues, plasma and saliva of HCC patients compared with healthy controls and groups of several benign liver diseases and other leading cancers. Its level was significantly reduced after curative hepatectomy but significantly elevated again if HCC recurrence occurred. Salivary lnc-PCDH9-13:1 showed reasonable specificities and sensitivities for detecting HCC compared with several control groups. Furthermore, the overexpression of lnc-PCDH9-13:1 promotes cell proliferation and migration in vitro.
interpretationSalivary lnc-PCDH9-13:1 is a desirable biomarker for early HCC. It may help warrant prospective validation with larger sample sizes in multi-centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.